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Congenital hyperinsulinaemic hypoglycaemia (HH) can occur in isolation or it may present as
part of a wider syndrome. For approximately 40%-50% of individuals with this condition,
sequence analysis of the known HH genes identifies a causative mutation. Identifying the
underlying genetic aetiology in the remaining cases is important as a genetic diagnosis will
inform on recurrence risk, may guide medical management and will provide valuable insights
into β-cell physiology. We sequenced the exome of a child with persistent diazoxide-responsive
HH, mild aortic insufficiency, severe hypotonia, and developmental delay as well as the unaf-
fected parents. This analysis identified a de novo mutation, p.G403D, in the proband’s CAC-
NA1D gene. CACNA1D encodes the main L-type voltage-gated calcium channel in the
pancreatic β-cell, a key component of the insulin secretion pathway. The p.G403D mutation
had been reported previously as an activating mutation in an individual with primary hyper-
aldosteronism, neuromuscular abnormalities, and transient hypoglycaemia. Sequence analysis
of the CACNA1D gene in 60 further cases with HH did not identify a pathogenic mutation.
Identification of an activating CACNA1D mutation in a second patient with congenital HH con-
firms the aetiological role of CACNA1D mutations in this disorder. A genetic diagnosis is impor-
tant as treatment with a calcium channel blocker may be an option for the medical
management of this patient.
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Hyperinsulinaemic hypoglycaemia (HH) is characterized by unregu-
lated insulin secretion despite low blood glucose with prompt treat-
ment essential in order to avoid seizures and permanent brain injury.
Diazoxide is an effective treatment for the majority of cases with HH
but for those who do not respond somatostatin analogues may some-
times be effective.1,2
Persistent HH is most commonly a result of a monogenic aetiol-
ogy with mutations in 9 genes described over the past 20 years.2
Each responsible gene was discovered either by linkage studies or via
a candidate gene approach and collectively mutations in these genes
are identified in 40%-50% of cases with persistent HH.3 An absence
of mutations in the remainder of patients suggests that novel etiolog-
ical genes remain to be discovered.
In addition to the 9 recognized monogenic subtypes of HH,
mutations in many genes have been reported where HH is a feature
of a syndrome in some individuals.4 It therefore seems likely that
gene discovery studies to search for novel HH genes will identify rare
mutations in known multisystem disease-causing genes where HH
has not previously been reported or is a minor feature.
Whilst next-generation sequencing (NGS) has revolutionized
gene discovery studies outside of this condition, no novel disease
genes have been identified in patients with persistent HH. There are
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likely to be several reasons for this; it may reflect the genetic hetero-
geneity of HH which makes replication studies to confirm pathoge-
nicity of novel variants more difficult or that the HH in the patients
previously screened is not monogenic. As patients with persistent
early-onset syndromic disease have the highest probability of having
a monogenic aetiology these individuals represent good candidates
for gene discovery studies.
1 | METHODS
We undertook exome sequencing in an individual with persistent HH
diagnosed at birth and her unaffected parents to search for a de novo
mutation as previously described.5 Mutations in the 9 known HH
genes had been excluded. The patient was diagnosed with HH shortly
after birth when blood glucose was found to be 1.2 mmol/L (22 mg/
dL) with corresponding insulin 21 μU/mL; she was treated with diaz-
oxide(13 mg/kg/day). She was born large for gestational age with a
birth weight greater than the 99th percentile, consistent with
increased insulin secretion in utero. Bradycardia was detected on a
prenatal echocardiogram at 27 weeks gestation with mild aortic
insufficiency diagnosed at birth. Additional features included umbilical
hernia, hypermetropia, severe axial hypotonia, and seizures (Table 1).
At the age of 5 years, the patient no longer required diazoxide ther-
apy and currently remains off all treatment for HH at the age of
9 years 4 months. The study was conducted in accordance with the
Declaration of Helsinki with informed parental consent given on
behalf of the child.
Target enrichment was carried out using the Agilent SureSelect
All Exon v5 capture kit (Agilent, Santa Clara, California). 100-bp
paired-end reads were sequenced on a HiSeq 2 500 (Illumina, San
Diego, California). Analysis was carried out following the best practice
guidelines for GATK from the Broad Institute (https://software.
broadinstitute.org/gatk/best-practices/). Sequence reads were
aligned to the hg19/GRCh37 human reference genome with BWA-
MEM with the mean target coverage for the proband of 64 reads per
base and 91% of targeted bases covered by at least 20 reads. Var-
iants were called using GATK and annotated with Alamut (Rouen,
France). Heterozygous variants were filtered by removing non-coding
and synonymous variants, variants in the Exome Aggregation Consor-
tium or databases single nucleotide polymorphism (dbSNP) and those
present in either parent. De novo mutations were confirmed by San-
ger sequencing (details of primers are available on request).
The 49 coding exons and the intron/exon boundaries of CAC-
NA1D (NM_000720.3) were sequenced using targeted NGS in 60 indi-
viduals with diazoxide-treated HH diagnosed before 12 months in
whom mutations in the 9 known genes had been excluded. In this
cohort, the median age at diagnosis of HH was 3 weeks (range: 0-12
months). Six patients had cardiac defects which included a heart mur-
mur (n = 1), patent ductus arteriosus (n = 1), ventricular septal defect
(n = 2), or hypertrophic cardiomyopathy (n = 2).
2 | RESULTS AND DISCUSSION
Exome sequencing of this family trio identified a single de novo mis-
sense substitution, p.Gly403Asp (c.1208G>A) in the CACNA1D gene
(figure 1). Analysis of the sequence traces showed that the alleles
were balanced, suggesting that this was more likely to be a germline
mutation rather than a postzygotic event. In silico analysis predicted
the variant was likely to be pathogenic and that the affected residue
was highly conserved (Alamut). According to the recommendations of
the American College of Medical Genetics and Genomics and the
Association of Molecular pathology the evidence to support pathoge-
nicity of this variant is strong.6
Targeted NGS of CACNA1D in 60 further patients did not iden-
tify a pathogenic variant. The absence of mutations may reflect the
low proportion of individuals with cardiac disease in the cohort (6 of
60) or it may represent the low prevalence of CACNA1D mutations in
individuals with HH.
A search of the literature identified the same de novo germline
mutation in an individual with primary hyper-aldosteronism and over-
lapping clinical features which included congenital heart defects
(biventricular hypertrophy and ventricular septal defect), seizures and
neuromuscular abnormalities. Additional features not present in our
patient were pulmonary hypertension, cortical blindness, and primary
hyper-aldosteronism.7 The reason(s) for the phenotypic differences
between our patient and the patient previously reported with the
same mutation are not understood, but may result from genetic
and/or environmental modifiers.
In the previously published patient with the same mutation, tran-
sient hypoglycaemia of unknown duration was diagnosed on the sec-
ond day of life and had been treated with diazoxide and
hydrocortisone. She had also been born large for gestational age
(4.4 kg) consistent with increased insulin secretion in utero.7 HH was
not reported in a second individual with a different de novo germline
CACNA1D mutation (p.Ile770Met) in the same series which suggests
that the presence of hypoglycaemia may be mutation specific.7
TABLE 1 Clinical characteristics of the proband with a de novo p.
Gly403Asp CACNA1D mutation
Sex Female
Birth weight (gestation) 4.5 kg (37 weeks)
Birth weight percentile >99th
Current age 9 years 4 months
Hyperinsulinaemic hypoglycaemia
Age at diagnosis Birth
Insulin at diagnosis 21 μU/mL
Glucose at diagnosis 1.2 mmol/L (22 mg/dL)
Initial treatment (dose)
and duration
Diazoxide (13 mg/kg/day) 5.5 years
Current treatment None
Additional clinical features
Heart defects Prenatal bradycardia, mild aortic
insufficiency
Neuromuscular defects Severe axial hypotonia and limb
spasticity, seizures
Other features Umbilical Hernia, Hypermetropia. Poor
weight gain
Aldosterone (normal
range)
9.3 ng/dL (3.4-27.3)
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Whilst it is possible that the HH in our patient and the previously
reported case is unrelated to the CACNA1D mutation, the high
expression of CACNA1D in the pancreas suggests that the mutation
is causative of the HH in both individuals.7,8 In addition, the presence
of HH in 2 of 3 individuals now reported with a germline CACNA1D
mutation is in keeping with the prevalence of HH in other
multisystem diseases such as Timothy syndrome, which results from
dominant mutations in CACNA1C.9
CACNA1D encodes an L-type voltage-gated calcium channel that
has a key role in insulin secretion from pancreatic β-cells.8 Electrophysi-
ological studies have demonstrated that mutant p.Gly403Asp channels
activate at lower membrane potentials and exhibit impaired
FIGURE 1 A, An integrative genomics viewer (IGV) screenshot showing the sequencing reads (grey bars) mapping to exon 8 of the CACNA1D
gene located at genomic position g.53,673,804 on chromosome 3. The reference nucleotide sequence and the amino acid translation are
provided under the sequencing reads. The heterozygous substitution of a guanine (G) to an adenine (A) at nucleotide position 1208 in 8 of the
18 sequencing reads is highlighted in green. B, The Sanger sequencing trace for the variant. The top trace is the reference while the bottom is
the patient’s sample. The heterozygous substitution of a guanine (G) to an adenine (A) is highlighted.
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inactivation.7 As influx of Ca2+ into the β-cell triggers insulin release fol-
lowing membrane depolarisation, we hypothesize that opening of the
channels at a lower membrane potential and a failure to close the chan-
nel would result in the dysregulated insulin secretion observed in our
patient.
L-type calcium channels are pharmacologically sensitive to dihy-
dropyridines which bind to and close the channel.10 The patient
reported by Scholl et al was treated with a dihydropyridine which
resulted in a normalization of blood pressure and resolution of the
biventricular hypertrophy.7 Whilst our patient was successfully trea-
ted with diazoxide for 5 years it seems possible that the HH may
have also responded to a calcium channel blocker. Treatment with a
dihydropyridine might also be effective for the management of the
extra-pancreatic features in our patient.
In conclusion, we report the first mutation detected in a novel
disease-causing gene by NGS in an individual with persistent HH. The
identification of an activating p.G403D mutation in 2 unrelated patients
with congenital HH supports the role of CACNA1D as an aetiological
gene for HH, and screening for mutations in this gene should be consid-
ered in an individual with HH in addition to heart defects.
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